Antje Blank

University Hospital Heidelberg

Germany

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

90%

Pharmacotherapy

100%

Pharmacokinetic

70%

Cytochrome P450

50%

Antiviral Therapy

50%

Drug Utilization

40%

Drug Development

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles17

Dose‐dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin

Article Link

Year:

2024

Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

Article Link

Year:

2024

Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes

Article Link

Year:

2024

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial

Article Link

Year:

2024

Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial

Article Link

Year:

2024

Effect of Tacrolimus Formulation (Prolonged-Release vs Immediate-Release) on Its Susceptibility to Drug-Drug Interactions with St. John's Wort

Article Link

Year:

2024

Evaluation of Hydroxychloroquine as a Perpetrator on Cytochrome P450 (CYP) 3A and CYP2D6 Activity with Microdosed Probe Drugs in Healthy Volunteers

Article Link

Year:

2024

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

Article Link

Year:

2023

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults

Article Link

Year:

2023

Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine

Article Link

Year:

2023

Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach

Article Link

Year:

2023

Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach

Article Link

Year:

2023

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D

Article Link

Year:

2023

Evaluation of the drug-drug interaction potential of the novel hepatitis B and D virus entry inhibitor bulevirtide at OATP1B in healthy volunteers

Article Link

Year:

2023

Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory Study

Article Link

Year:

2023

Immune Response to COVID-19 mRNA Vaccination in Previous Nonresponder Kidney Transplant Recipients After Short-term Withdrawal of Mycophenolic Acid 1 and 3 Months After an Additional Vaccine Dose

Article Link

Year:

2023

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202) : a multicentre, randomised, parallel-group, open-label, phase 2 trial

Article Link

Year:

2023

Collaborators4

Jürgen Burhenne

Head of the Analytical Chemistry Lab

Heidelberg University

GERMANY

Andreas D. Meid

GERMANY

Michael Lanzer

Professor of Parasitology

UniversitätsKlinikum Heidelberg

GERMANY

Walter E. Haefeli

GERMANY

How do I reach out?

Meet Kite AI